Back to Search
Start Over
Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
- Source :
- Gastroenterology Research and Practice, Vol 2011 (2011)
- Publication Year :
- 2011
- Publisher :
- Hindawi Limited, 2011.
-
Abstract
- Sorafenib is an oral angiogenetic multikinase inhibitor approved in the treatment of renal and hepatocellular carcinoma. Bleeding and venous thrombotic events have been described with angiogenetic agents but cerebrovascular accidents are rarely reported. We report two cases of patients with hepatocellular carcinoma who developed a cerebrovascular accident while on sorafenib. Neither patient had any risk factors for the cerebrovascular events apart from gender and age in the second patient. Laboratory data were noncontributory. The head CT scan did not reveal acute abnormalities. No hemodynamically significant stenosis was visible in the carotid ultrasound, and the echocardiogram showed normal size of the heart chambers and normal systolic function of the left ventricle. Sorafenib was discontinued in both cases. Physicians should monitor patients receiving sorafenib for neurologic symptoms, and in the absence of other etiology, prompt discontinuation of this drug should be considered.
- Subjects :
- Diseases of the digestive system. Gastroenterology
RC799-869
Subjects
Details
- Language :
- English
- ISSN :
- 16876121 and 1687630X
- Volume :
- 2011
- Database :
- Directory of Open Access Journals
- Journal :
- Gastroenterology Research and Practice
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.fc9044db2a4e40b3a327ce542abe9b69
- Document Type :
- article
- Full Text :
- https://doi.org/10.1155/2011/616080